Navigation Links
Sosei Announces Approval to Start AD 923 Phase III Studies in Europe
Date:11/28/2007

TOKYO, November 28 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), a biopharmaceutical company, today announces that it has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the Phase III clinical trial programme for its fentanyl sublingual spray (AD 923), an opioid analgesic for the treatment of cancer breakthrough pain.

The clinical trial authorisation (CTA) covers two multi-centre pivotal Phase III efficacy studies followed by an open label safety study. Patient enrolment in the UK is expected to commence before the end of the year and will be the subject of a separate announcement. Applications have been made in other European countries and further patient recruitment will be initiated as soon as approval is received from the relevant local regulatory body.

This first CTA in a major European country will also trigger the receipt of a project milestone payment under the AD 923 Licence Agreement signed with Mundipharma in June 2006.

Mr Shinichi Tamura, President & CEO of Sosei, said: "Receipt of our first Phase III CTA represents an important milestone in the evolution of Sosei and the continuing progress of the AD 923 development programme. We look forward to enlisting our first patients in the trial".

Notes to Editors:

About Sosei

Sosei Group Corporation is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan.

For further information about Sosei, please visit http://www.sosei.com

About AD 923

AD 923 is an optimised, sublingual formulati
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Sosei and Vectura Announce Start of Phase II Studies of QVA149 for the Treatment of COPD
2. Sosei Announces Update on Phase I Trials for SD118
3. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
4. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
5. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
6. HEI, Inc. Announces Sale of RFID Division Assets
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
9. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
10. Brooke Franchise Corporation Announces Selected July Results
11. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2015)... 2015 Looking for a graduate ... impact your career? The Master of International Business, ... in multinational companies and for professionals seeking a ... global landscape, differences in culture, religion, government, and ... program develops the global competence and confidence needed ...
(Date:5/3/2015)... MA (PRWEB) May 03, 2015 SpineFrontier, ... clearance from the FDA to produce and market their ... device can be used in outpatient settings and is ... The alternate posterior approach has been extensively researched and ... 510k approval to use this approach in conjunction with ...
(Date:5/3/2015)... HealthPostures, a pioneering ergonomics company that ... the , May 5 - 7, 2015 Minnesota Safety ... the conference include its bestselling TaskMate sit stand solutions. ... 6100 TaskMate Executive. Features of the 6100 TaskMate Executive ... extended platform work surface and supply holders. Weighing 50 ...
(Date:5/2/2015)... Ticket Down has secured additional inventories of ... awaited event today, Saturday, May 2nd at the MGM Grand ... be able to secure tickets for both the actual fight ... fans have wanted for more than five years was finally ... will step inside the ring to fight Manny “Pac-Man” Pacquiao ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 “ ActOn ” ... which takes a look at the latest and coolest applications ... the host of AppWatch and technology expert, conducted the app ... to get connected with organizations to make a difference. , ... are very few things that aren’t about money, which is ...
Breaking Medicine News(10 mins):Health News:The Saint Louis University's Master of International Business Is Now Enrolling For Fall 2015 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 3Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2
... is reason to believe that a gene-based treatment for heart ... of new blood vessels in hearts with severe hardening of ... thousands of patients suffering with heart disease.// ,Treatment ... surgical procedures that open blocked arteries and improve blood flow ...
... A new study from Brazil has found that coffee ... blood levels of cholesterol and the protein homocysteine.High levels ... disease. Some of the compounds, called terpenoids, are known ... Right, of Marylandl University Hospital ,US, explained that "it ...
... Children living in damp homes run greater asthma risks,say ... could double the risk of asthma, say researchers. ,A ... in damp homes not only increased the risk of ... repeated colds and skin allergies. People living in damp ...
... is an inherited blood disorder that affects red blood ... cells that contain an abnormal type of hemoglobin. Sometimes ... passing through small blood vessels. When sickle-shaped cells clump ... pain severe enough to require hospital admission. // ...
... has approved a new method to treat women suffering excessive ... the tissue at fault. Millions of women suffer menorrhagia, benign ... than 20 tampons in a single day. Thousands of women ... try hormone treatment.// ,The other option is to ...
... That's been the mantra of the media as dozens of ... clamor for the potent antibiotic. But if the supply dwindles, ... used, including a previous generation's wonder drug: penicillin. Although alternatives ... to get attention. , // ,It helped that ...
Cached Medicine News:
(Date:5/1/2015)...  Legendary actor and director Danny Glover ... designed to educate and encourage patients with neurologic conditions, ... (PBA) and to speak with their physician. The campaign ... ability to cry and laugh on cue and how ... people living with PBA episodes. While PBA ...
(Date:5/1/2015)... 1, 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), ... commercialization of innovative therapies for the treatment of acute ... Morris , chief financial officer  will be participating in ... as follows: Mizuho Third Annual Healthcare Corporate ... Berkshire Place, New York ...
(Date:4/30/2015)... 30, 2015 Omnicell, Inc. (NASDAQ: OMCL ), ... to healthcare systems, today announced results for its first ... Revenue for the first quarter of 2015 was $116.2 ... quarter of 2014, and down $5.3 million or 4.4% ... quarter 2015 net income as reported in accordance with ...
Breaking Medicine Technology:Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA), a Little Known but Widespread Neurologic Condition 2Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA), a Little Known but Widespread Neurologic Condition 3AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May 2Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20Omnicell Announces First Quarter 2015 Results 21Omnicell Announces First Quarter 2015 Results 22Omnicell Announces First Quarter 2015 Results 23Omnicell Announces First Quarter 2015 Results 24Omnicell Announces First Quarter 2015 Results 25Omnicell Announces First Quarter 2015 Results 26Omnicell Announces First Quarter 2015 Results 27
... 2011 Telik, Inc. (Nasdaq: TELK ) reported a ... three months ended December 31, 2010, compared with a net loss ... in 2009.  For the year ended December 31, 2010, net loss ... loss of $23.7 million, or $0.44 per share, for the year ...
... Amgen (Nasdaq: AMGN ) today announced ... study of 1,776 advanced cancer patients with different types ... or multiple myeloma, which compared XGEVA ™ (denosumab) ... The study, which appeared today in the Journal ...
Cached Medicine Technology:Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance 2Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance 3Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance 4Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance 5The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 2The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 3The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 4The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 5The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 6The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 7The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 8
The opaque outer circle will white-out even the darkest iris, making your pupil the only spot of black in a sea of white....
This lens gives the appearance of mystery and mayhem behind the blackest of eyes....
Soft silicone brush tip allows atraumatic brushing and manipulation of retina surface. Silicone brush extends 3mm beyond end of cannula. Luer lock hub for easy, secure connection to a backflush handl...
Healon vitreous aspirating cannula, 21 gauge....
Medicine Products: